Comparative Pharmacology
Head-to-head clinical analysis: BRETHINE versus METAPROTERENOL SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHINE versus METAPROTERENOL SULFATE.
BRETHINE vs METAPROTERENOL SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing intracellular cAMP, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Selective beta-2 adrenergic receptor agonist that activates adenylate cyclase, increasing intracellular cyclic AMP leading to bronchodilation and inhibition of mast cell mediator release.
5 mg orally three times daily; may increase to 10 mg if needed; maximum 20 mg daily. Subcutaneous: 0.25 mg, may repeat once in 15-30 minutes (not to exceed 0.5 mg in 4 hours).
2.5 mg (0.25 mL of 1% solution) by nebulization every 6-8 hours. For oral, 20 mg every 6-8 hours.
None Documented
None Documented
3-8 hours (terminal); shorter in children and smokers; prolonged in hepatic impairment
Terminal elimination half-life: 2-6 hours. Clinical context: Shorter half-life requires frequent dosing; prolongation in renal impairment.
Renal: 50-60% as unchanged drug and metabolites; biliary/fecal: 20-30%
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist